# A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body

> **NCT02154646** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 6 (actual)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** LY2157299
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02154646
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-09
- **Final completion:** 2015-07
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2016-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02154646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02154646, "A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02154646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*